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The ethics of clinical trials involving patients with infec- 
tious diseases has received a great deal of attention 
recently in both the lay and the scientific press. In the 
Spring of 1997, President Clinton publicly apologized to 
the survivors and families of the US Public Health Ser- 
vice-sponsored Tuskegee Syphilis Study, recognizing that 
the study investigators wrongly had violated both the 
subjects’ rights and the ethics of scientific conduct.’ More 
recently, Lurie and Wolfe described why they believed 
that many of the current placebo-controlled trials to eval- 
uate the prevention of perinatal human immunodefi- 
ciency virus (HIV) transmission in developing countries 
are unethical. In their opinion, new “standards of 
research” were needed to preclude similarly designed 
studies in the future.2 Their article and the accompany- 
ing editorial, which linked the justification of these trials 
with those used for the Tuskegee study,’ have engen- 
dered a heated debate concerning the ethics of recent 
placebo-controlled clinical trials.* The same editorial also 
raised ethical concerns about a placebo-controlled tuber- 
culosis (TB) prevention study.3 Though the ‘Tuskegee 
study, the HIV-prevention trials, and the TB-prevention 
study had disparate locations, patient populations, and 
time-frames, all involved groups of underserved individ- 
uals who otherwise did not have access to the highest 
standards of clinical care. 
ETHICAL STANDARDS 
Ever since Beecher described abuses in clinical research 
in 1966,5 a number of national and international guide- 
lines for clinical research have been instituted and 
reviewed.6-‘0 A consensus has developed that, for a trial 
to be ethical, there must exist an honest uncertainty in 
the medical community, or equipoise, between treatment 
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options in a study that has a reasonable chance of resolv- 
ing this controversy.9 Freedman defined “clinical 
equipoise” as “an honest, professional disagreement 
among expert clinicians about the preferred treatment” 
in a defmed group of patients.’ 
For a clinical trial to be considered ethical, additional 
criteria must be met besides the existence of an informed 
disagreement among experts as to the best treatment. 
Patients must have free choice and access to all infor- 
mation necessary to make an informed decision whether 
or not to participate in a study, and the protocol must be 
reviewed by appropriate independent review boards.” 
Furthermore, the importance of including patients in the 
design of clinical trials has been recognized.12J3 In stud- 
ies that use subjects in developing countries, local sci- 
entists and review boards should also be involved in the 
design and conduct of the study in addition to the above 
criteria.l*s’j 
RECENT CONTROVERSIAL TRIALS 
The controversy surrounding the HIV-prevention trials 
in developing countries is due to the fact that these inves- 
tigations do not satisfy the criteria of clinical equipoise. 
This standard does not preclude the use of placebos. 
When therapies of proven efficacy do not exist, placebo- 
controlled trials are both necessary and ethical. However, 
no one is arguing that the intervention studied in AIDS 
Clinical Trial Group (ACTG) 076 for the prevention of 
perinatal transmission of HIV is unproven, rather that this 
treatment is not possible in many developing countries. 
The inclusion of placebos in clinical trials is unethical 
when proven therapies exist.16 The Declaration of 
Helsinki clearly states that “In any medical study, every 
patient-including those of a control group, if any- 
should be assured of the best proven diagnostic and ther- 
apeutic method.“” 
It has been argued that a placebo-controlled trial is 
the most expeditious method for providing “lifesaving 
answers”;l’ however, the Declaration of Helsinki takes an 
unambiguous position on this issue:“In research on man, 
the interest of science and society should never take 
precedence over considerations related to the wellbeing 
[sic] of the subject.“l’ 
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Additional arguments in defense of these placebo- 
controlled studies in developing countries include the 
involvement of local scientists in their design and con- 
duct.15,1s The inherent conflicts of interest that exist for 
American researchers conducting clinical trials also exist 
for researchers in developing countries. Just as the 
involvement of US government officials and scientists 
was not enough to protect the rights and interests of 
African-Americans in Tuskegee, the inclusion of local sci- 
entists and officials in developing countries is a necessary 
but not sufficient, condition for an ethical trial. 
Although recent public attention has focused on 
HIV-prevention trials, other equally important cases 
exist. Between March 1993, and April 1995, HIV-infected, 
purified-protein-derivative (PPD) skin test-positive per- 
sons were randomized to placebo or one of three active 
prevention arms in a TB prevention trial conducted in 
Uganda. The investigators justified the inclusion of a 
placebo group by the lack of data on the risks and ben- 
efits of TB preventive therapy in HIV-infected, PPD-pos- 
itive persons. Observation of the placebo arm continued 
until December 1995, when the second interim analy- 
sis demonstrated a 67% reduction in TB among those 
who received isoniazid compared with the placebo 
group.i9 
Although the investigators claimed that clinical 
equipoise justified the inclusion of a placebo arm, this 
claim lacks credibility. In the United States by 1993, iso- 
niazid chemoprophylaxis for HIV-infected, PPD-positive 
persons was the standard of care.20z21 Cohort data,22,Z3 
including those from randomized trials,24,25 supported 
the recommendations of the Centers for Disease Con- 
trol as well as the recommendations of the American 
Thoracic Society for the use of preventive therapy in 
HIV-infected, PPD-positive persons. The US-based chemo- 
prophylaxis trial for HIV-infected, PPD-positive persons, 
begun in September 1991 (ACTG 177Kommunity Pro- 
grams for Clinical Research on AIDS 004), did not 
include a placebo arm. A placebo arm would have been 
unethical because the US consensus was, and remains 
so, that isoniazid is more effective than placebo, with 
acceptable toxicities, for the prevention of TB in HIV- 
infected, PPD-positive persons. Clinical equipoise did 
not exist. 
There was not only more than adequate information 
to show that TB-preventive therapy was both effective 
and crucial for HIV-infected, PPD-positive patients in the 
United States, but similar information existed also for 
such patients in developing countries. By and during 
1993, TB-preventive therapy had already been demon- 
strated to be effective in HIV-infected, PPD-positive per- 
sons living in developing countries (Zambia and 
Haiti).“4,2s In addition, policy analyses of TB prevention 
had demonstrated the importance of chemoprophylaxis 
for HIV-infected persons in similar settings.26 There was 
no ethical justification for another placebo-controlled 
study in HIV-infected, PPD-positive persons. Comparison 
with the local standard of care, rather than clinical 
equipoise, apparently was the rationale for inclusion of 
the placebo group. 
WHOSE “STANDARD OF CARE”? 
The specifics of the HIV and TB prevention trials differ; 
however, in each case the use of a placebo occurred in 
a developing country when it would not have occurred 
in the United States. Study participants in these countries 
did not have access to the standards of health care avail- 
able in the United States. 
Those in favor of the HIV perinatal transmission, 
placebo-controlled studies have argued that they are both 
ethical and important because they provide people living 
in low-resource countries with the possibility of a treat- 
ment for which the “standard of care” is “no treatment.“1s~27 
Accepting that a local “standard of care” can be used as 
the comparison arm, even when that standard of care is 
gravely inadequate, sets dangerous precedents both over- 
seas and in the United States. For example, if it is per- 
missible to conduct placebo-controlled trials overseas to 
determine whether a less expensive medical treatment 
provides some benefit over no treatment although more 
expensive proven therapies exist, then what is the ethical 
basis of preventing such trials in the United States? Millions 
of Americans currently lack health care insurance, and the 
disparities in access to health care in the United States 
have been well documented.28 Will trials testing less expen- 
sive therapies be approved next that allow low-income or 
vulnerable populations in the United States to be research 
subjects in protocols that include study arms less effective 
than treatments available to the rest of the population? 
THE ROOT OF THE PROBLEM: 
TWO-TIERED HEALTH CARE 
The debate over the ethics of clinical trials will generate 
more heat than light unless we address what is at the 
root of the problem-the grossly inequitable distribution 
of health care resources both between countries and 
within countries. At present, deeply committed 
researchers and policy makers in both developing and 
industrialized countries sit on both sides of the fence 
arguing about placebo-controlled trials. The position of 
some that universal ethical standards should be applied 
equally across countries cannot be refuted; nor can the 
concern of others that life-saving interventions are 
needed to prevent and treat deadly infectious diseases 
where no treatments are currently available. Unless we 
address the gross inequalities at the root of this dilemma, 
citizens enmeshed on the two sides of the debate will be 
Two-Tiered Health Care: Ethical Problems in Clinical Trials / Brewer and Heymann 125 
caught like the two mothers facing Solomon when he 
was to divide a baby in half. Receiving either half of the 
baby is an untenable solution. The only solution is to 
address the gross inequalities in health care. 
Some might argue that addressing the inequitable 
distribution of health care resources is not the responsi- 
bility of the medical community nor is it within its capa- 
bilities. We disagree. The treatment and prevention of 
infectious diseases is a sensible place to start addressing 
the inequities in health care. Inequities in the treatment 
of infectious diseases may be more readily addressed than 
those in the treatment of some other conditions because 
their prevention and treatment often require less infra- 
structure than, for example, conditions that require sur- 
gical treatment. Furthermore, one could argue that 
industrialized countries should be concerned with the 
treatment of infectious diseases in developing countries, 
not only for reasons of equity and humanity, but also out 
of self-interest. Infectious diseases know no borders. The 
transmission of infectious diseases from developing coun- 
try populations to those of industrialized countries, as 
well as the reverse, has been well documented. 
ADDRESSING THE PROBLEM 
How do we conduct ethical clinical trials while working 
to decrease the inequities in the distribution of health 
care resources? Appropriate research designs and max- 
imal use of existing data offer ways to avoid using 
placebo arms in underserved populations. Oral rehydra- 
tion therapy (ORT) provides an important example of 
such research designs. Early studies of ORT compared 
the need for intravenous fluids with and without ORT. 
Although patients received needed therapy, these stud- 
ies demonstrated that ORT is an equally good and far 
less expensive treatment. The initial studies took place 
in carefully controlled settings, and were later followed 
by field trials. These were not placebo-controlled stud- 
ies, yet ORT has become the accepted treatment for diar- 
rhea1 disease and has saved countless lives in developing 
countries.29 
Using previously published comparison groups rather 
than placebo arms is another option. Although the diffi- 
culties of using historical controls are well known, such 
historical controls none-the-less can prove to be bench- 
marks for assessing the safety and effectiveness of new 
dosing strategies for compounds of known effectiveness. 
Clinical trials that test a known effective treatment 
against a less expensive, unknown, treatment are not eth- 
ical if the less expensive treatment does not have the 
potential to offer benefits to the patients involved. How- 
ever, in many cases, the first treatments shown to be effec- 
tive also have high levels of side effects. Shorter courses 
of treatment and lower-dose courses of treatment, which 
may have fewer side effects and require less time in hos- 
pitals or clinical settings, have the potential to offer impor- 
tant benefits to patients. When the anticipated net 
benefits of the new therapy are equal to, or better than, 
the anticipated net benefits of the previous therapy, the 
conditions for an ethical trial exist. Such equivalence tri- 
als are an important avenue to follow.3o They provide 
important information without allowing research to slip 
into the chasm created by inequities in care and to end 
up inadvertently promoting these inequities. 
Several solutions exist for addressing simultaneously 
inequalities in the availability of infectious disease treat- 
ments. One is to have industrialized countries continue 
to pay for medications at prices that cover research and 
development costs and thus provide incentives for com- 
panies to continue to invest in the development of new 
medications. At the same time, however, they should offer 
these medications to patients in developing countries at 
the far lower marginal cost of producing them. A similar 
approach is already being used to prevent river blindness 
in many countries. Merck & Co., Inc., is donating iver- 
mectin to treat onchocerciasis in Africa and Latin Amer- 
ica while charging for its use in prevention of heartworm 
in American dogs. Two-tiered pricing, with one for devel- 
oped and one for developing countries, is far better than 
two-tiered access to health care. 
It will not be simple to ensure that drug companies 
receive an income sufficient to cover research and devel- 
opment costs and the incentive to continue developing 
new drugs from the higher prices in industrialized coun- 
tries while providing developing countries access at 
lower costs. However, it can be done, if national and inter- 
national organizations begin to use as much energy to 
address the gross inequalities in health care as they have 
used to address other health questions. 
In clinical research, a number of factors have led to 
an increase in collaborations between investigators of 
industrial and of developing countries. Socio-economic 
advances in many countries have improved the infra- 
structure necessary to conduct research. Investigators in 
industrial and low-resource countries have formed acad- 
emic partnerships capable of completing trials. Most 
major infectious causes of morbidity and mortality, such 
as TB, HN and malaria, are more prevalent in low-resource 
countries. Studies also are conducted in developing coun- 
tries because of the belief that there are fewer constraints 
on investigators. For all these reasons, issues and ethical 
conflicts associated with the conduct of research in vul- 
nerable populations is likely to increase, not decrease, 
over the coming years. 
We need to recognize that the marked inequality in 
access to health care within countries and between coun- 
tries is as important a threat to the world’s health as any 
microbe we face. As scientists and clinicians, we should 
be using our collective intellectual resources to eradicate 
this scourge of mankind. 
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